MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Pfizer
Study ID
NCT05090566
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Key Dates

Start date
Oct 27, 2021
Status verified
Apr 2026
Primary completion
Feb 13, 2025
Completion
Mar 11, 2026

Study Design

Enrollment
46 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Sub-Study A
    BCMA-CD3 bispecific antibody + gamma secretase inhibitor
  • Experimental: Sub-Study B
    BCMA-CD3 bispecific antibody + immunomodulatory drug

Primary Outcome Measure

SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation [ Time Frame: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 35 days) ]

Locations (22)

Related coverage on Hipa.ai

Find similar trials in Gilbert, AZ

By condition

Related Studies